DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
Loading...
  • Stocks
  • /
  • Pharmaceuticals & Biotech
Updated 1h ago
AVTR logo

Avantor, Inc.NYSE:AVTR Stock Report

Market Cap US$10.7b
Updated 1h ago
Share Price
n/a
1Y24.2%
7D4.8%
1D-2.1%
Portfolio Value
​
View

Avantor, Inc.

NYSE:AVTR Stock Report

Market Cap: US$10.7b

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Avantor (AVTR) Stock Overview

Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. More details

AVTR fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Rewards

Trading at 9.6% below our estimate of its fair value

Earnings are forecast to grow 93.73% per year

Trading at good value compared to peers and industry

Risk Analysis

Interest payments are not well covered by earnings


AVTR Community Fair Values

Create Narrative

See what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

AN
AnalystConsensusTarget
6.6% overvalued intrinsic discount
AnalystConsensusTarget
•1mo ago

AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery

472
0
10
AN
AnalystLowTarget
29.3% overvalued intrinsic discount
AnalystLowTarget
•15d ago

Digital Transformation And Rising Costs Will Undermine Lab Chemicals Sector

83
0
0
AN
AnalystHighTarget
13.5% undervalued intrinsic discount
AnalystHighTarget
•1mo ago

Secular Trends And Cell Therapies Will Expand Markets Despite Risks

60
0
0

Top Analyst Narratives

AN
AnalystConsensusTarget
6.6% overvalued intrinsic discount
AnalystConsensusTarget
•1mo ago

AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery

472
0
10
AN
AnalystLowTarget
29.3% overvalued intrinsic discount
AnalystLowTarget
•15d ago

Digital Transformation And Rising Costs Will Undermine Lab Chemicals Sector

83
0
0
AN
AnalystHighTarget
13.5% undervalued intrinsic discount
AnalystHighTarget
•1mo ago

Secular Trends And Cell Therapies Will Expand Markets Despite Risks

60
0
0
View all narratives

Avantor, Inc. Competitors

Bio-Rad Laboratories

Symbol: NYSE:BIO
Market cap: US$10.1b

10x Genomics

Symbol: NasdaqGS:TXG
Market cap: US$10.0b

Bio-Techne

Symbol: NasdaqGS:TECH
Market cap: US$11.4b

Qiagen

Symbol: NYSE:QGEN
Market cap: US$9.2b

Price History & Performance

Summary of share price highs, lows and changes for Avantor
Historical stock prices
Current Share PriceUS$15.52
52 Week HighUS$16.05
52 Week LowUS$7.27
Beta0.89
1 Month Change11.17%
3 Month Change62.00%
1 Year Change24.16%
3 Year Change-26.48%
5 Year Change-64.74%
Change since IPO7.03%

Recent News & Updates

User avatar
Narrative Update • Sep 03

AVTR: Early Turnaround Progress Will Likely Struggle To Sustain Elevated Earnings Multiple

Analysts have lifted the fair value estimate for Avantor to $12 from $7, reflecting a series of higher Street price targets around $12 to $14 that are tied to recent Q2 earnings beats, early progress under the new CEO, and ongoing self help initiatives. Analyst Commentary Recent research updates on Avantor show a cluster of higher fair value and price targets after the Q2 earnings beat and the early phase of the new CEO's plan.
Seeking Alpha • Aug 28

Avantor: Smaller Green Shoots Of Organic Growth Returning Are Well Priced In

Summary Avantor has shown stabilization, with organic growth returning and leverage concerns receding as net debt declines. Avantor raised its full-year organic sales and adjusted earnings guidance, signaling a likely return to positive growth in H2. Margin improvement remains a key lever; every 1% margin gain could add $0.10 per share pre-tax, but topline growth is required. Shares have nearly doubled since April, reflecting improved outlook, but current valuations already price in much of the good news. Read the full article on Seeking Alpha
User avatar
Narrative Update • Aug 14

AVTR: Turnaround Progress And Sector Tailwinds Will Likely Define Next Phase

Analysts have lifted the Avantor fair value estimate from $10.31 to $14.56 after a series of price target increases across the Street. This reflects updated views on discount rate, revenue growth, profit margin, and future P/E assumptions following recent Q2 results and turnaround progress.
User avatar
Narrative Update • Jul 30

AVTR: Turnaround Execution And Sector Recovery Will Support Future Repricing

Analysts have raised Avantor's fair value estimate from $15.99 to $17.94, reflecting higher price targets across the Street following Q2 results and a management turnaround that is starting to appear in reported margins and growth assumptions. Analyst Commentary Recent Street commentary around Avantor has shifted toward a more constructive tone, with several firms resetting price targets higher following the latest Q2 earnings and early signs of progress under the new leadership team.

Recent updates

User avatar
Narrative Update • Sep 03

AVTR: Early Turnaround Progress Will Likely Struggle To Sustain Elevated Earnings Multiple

Analysts have lifted the fair value estimate for Avantor to $12 from $7, reflecting a series of higher Street price targets around $12 to $14 that are tied to recent Q2 earnings beats, early progress under the new CEO, and ongoing self help initiatives. Analyst Commentary Recent research updates on Avantor show a cluster of higher fair value and price targets after the Q2 earnings beat and the early phase of the new CEO's plan.
Seeking Alpha • Aug 28

Avantor: Smaller Green Shoots Of Organic Growth Returning Are Well Priced In

Summary Avantor has shown stabilization, with organic growth returning and leverage concerns receding as net debt declines. Avantor raised its full-year organic sales and adjusted earnings guidance, signaling a likely return to positive growth in H2. Margin improvement remains a key lever; every 1% margin gain could add $0.10 per share pre-tax, but topline growth is required. Shares have nearly doubled since April, reflecting improved outlook, but current valuations already price in much of the good news. Read the full article on Seeking Alpha
User avatar
Narrative Update • Aug 14

AVTR: Turnaround Progress And Sector Tailwinds Will Likely Define Next Phase

Analysts have lifted the Avantor fair value estimate from $10.31 to $14.56 after a series of price target increases across the Street. This reflects updated views on discount rate, revenue growth, profit margin, and future P/E assumptions following recent Q2 results and turnaround progress.
User avatar
Narrative Update • Jul 30

AVTR: Turnaround Execution And Sector Recovery Will Support Future Repricing

Analysts have raised Avantor's fair value estimate from $15.99 to $17.94, reflecting higher price targets across the Street following Q2 results and a management turnaround that is starting to appear in reported margins and growth assumptions. Analyst Commentary Recent Street commentary around Avantor has shifted toward a more constructive tone, with several firms resetting price targets higher following the latest Q2 earnings and early signs of progress under the new leadership team.
User avatar
Narrative Update • Jul 14

AVTR: Sector Tailwinds And Execution Risks Will Likely Shape Next Phase

Avantor's updated analyst price target moves from $9.92 to $10.31, with analysts citing refreshed sector views, recent target hikes into the $10.50 to $11 range, and a higher assumed future P/E multiple as key supports for the revised valuation framework. Analyst Commentary Recent research on Avantor reflects a split view, with some analysts pointing to improving sector conditions and revised price targets, while others focus on ongoing growth and margin challenges.
Analysis Article • Jun 17

Avantor (AVTR) Stock Could Be 34% Below Fair Value After Wolfe Research Downgrade

Wolfe Research’s new Underperform rating on Avantor (AVTR) has put fresh attention on the stock, as the firm pointed to ongoing growth and margin pressures, as well as market share losses in its VWR distribution business. See our latest analysis for Avantor. Avantor’s recent 1 day share price return declined 1.44%, extending a 7 day share price return decline of 3.43%. However, the 30 day share price return rose 25.59%, while the 1 year total shareholder return declined 27.22%. This indicates...
User avatar
Narrative Update • Jun 15

AVTR: Compressed Margins And Shrinking Real Revenue Will Weigh On Future Returns

Analysts have trimmed the fair value estimate for Avantor to $7.00, reflecting a series of lower price targets and continued concerns about shrinking real revenue, margin compression, and execution risk, even though some expectations remain for improved growth and profitability over time. Analyst Commentary Recent Street research on Avantor has leaned cautious, with several bearish analysts cutting price targets and highlighting ongoing operational and profitability challenges.
User avatar
Narrative Update • Jun 01

AVTR: Reset Expectations And Quality Expansion Will Support Turnaround Execution And Repricing

Analysts have trimmed Avantor's fair value estimate by about $0.48 to $15.99, as recent price target cuts and concerns about execution, market share trends, and confidence in the turnaround story temper prior expectations. Analyst Commentary Street research on Avantor has centered on whether the current share price already reflects execution risk and the uncertainties around the turnaround plan.
User avatar
Narrative Update • May 01

AVTR: Reset Expectations And Execution Progress May Support Future Upside

Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.
User avatar
Narrative Update • Apr 16

AVTR: Expanded Quality Control Capabilities Will Support Execution Turnaround And Future Share Repricing

Analysts have trimmed their average price targets on Avantor, and the updated fair value estimate now stands at about $16.47. This reflects a softer sentiment around the stock as research notes point to share losses, reduced investment, and questions about management's ability to stabilize the business.
User avatar
Narrative Update • Apr 02

AVTR: Reset Expectations And Share Repurchases May Support Future Upside

The analyst price target for Avantor has shifted lower to reflect a series of Street target cuts, including a move to $8.50. This change stems from concerns about share losses, constrained investment, and uncertainty over whether management can stabilize the business.
User avatar
Narrative Update • Mar 19

AVTR: Execution Turnaround In Core Franchise Will Drive Future Share Repricing

Analysts have lowered their price targets on Avantor, with the updated fair value estimate moving from about $17.68 to $16.13 as they factor in concerns about share losses, underinvestment, and uncertainty around management's ability to stabilize the business, along with a higher assumed discount rate and P/E multiple. Analyst Commentary Recent Street research has tilted cautious on Avantor, highlighted by a downgrade to Underweight with a US$8.50 price target and several cuts to prior price targets.
User avatar
Narrative Update • Mar 05

AVTR: Reset Expectations And Buybacks Will Support Future Upside Potential

Analysts have cut their average price target on Avantor by a few dollars to reflect lower fair value estimates, softer assumed revenue growth and profit margins, and a higher future P/E multiple in light of recent broad target reductions from firms across the Street. Several have moved targets in a $2 to $4 range, and one reset its view from $14 to $12.
Analysis Article • Feb 13

The Market Doesn't Like What It Sees From Avantor, Inc.'s (NYSE:AVTR) Revenues Yet As Shares Tumble 27%

Avantor, Inc. ( NYSE:AVTR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...
User avatar
Narrative Update • Feb 04

AVTR: Service Expansion And Execution Will Drive Upside From Reset Expectations

Narrative Update: Avantor Analyst Price Target Shift Analysts recently trimmed their price target on Avantor to $12 from $14. This reflects updated views on the life science tools sector and a Q4 outlook where many companies have already set softer expectations for 2026.
User avatar
Narrative Update • Jan 21

AVTR: Share Repurchases And Execution Risks Will Shape Turnaround Visibility

Analysts have trimmed their price target on Avantor by about $0.60, reflecting more cautious assumptions on revenue growth and future P/E. This is partly offset by slightly higher profit margin expectations and a marginally lower discount rate.
User avatar
Narrative Update • Jan 07

AVTR: Execution Turnaround And Review Process Will Unlock Share Repricing Potential

Avantor's analyst price targets and fair value estimates have inched higher to around $17.68 per share. At the same time, lower assumed revenue growth, a higher discount rate, a reduced future P/E, and sharply higher profit margin expectations reflect analysts' mixed views following recent downgrades and concerns about execution and visibility.
User avatar
Narrative Update • Dec 14

AVTR: Share Repurchases Will Drive Upside As Turnaround Visibility Improves

Analysts have modestly lowered their price targets on Avantor by a few dollars per share, generally to the low to mid teens in dollar terms. They cite reduced guidance, weaker quarters and limited visibility around the company’s turnaround and strategic review.
User avatar
Narrative Update • Nov 28

AVTR: Share Repurchase Initiative And Execution Will Shape Recovery Prospects Ahead

Analysts have lowered their price target for Avantor from $14 to $12 per share, citing a weak quarter, reduced guidance, and ongoing execution risks as primary concerns behind the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets ahead of quarterly results, reflecting improved confidence in Avantor’s long-term positioning despite current volatility.
User avatar
Narrative Update • Nov 14

AVTR: Share Repurchase And Execution Will Define Turnaround Prospects In 2025

Avantor’s analyst price target has decreased from $13.80 to $13.64. Analysts cite reduced company guidance, execution risks, and ongoing uncertainty surrounding its earnings outlook as key factors driving the revision.
Analysis Article • Nov 01

Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

There's been a major selloff in Avantor, Inc. ( NYSE:AVTR ) shares in the week since it released its third-quarter...
User avatar
Narrative Update • Oct 31

AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery

Avantor’s analyst price target has been reduced from $14.40 to $13.80 per share, as analysts cite ongoing operational headwinds and limited near-term earnings visibility following recent downgrades and mixed guidance. Analyst Commentary Recent analyst notes on Avantor capture a divided outlook, reflecting both positive updates from some firms and notable caution from others as the company contends with ongoing operational challenges.
Analysis Article • Oct 28

There's No Escaping Avantor, Inc.'s (NYSE:AVTR) Muted Earnings Despite A 28% Share Price Rise

Avantor, Inc. ( NYSE:AVTR ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...
User avatar
Narrative Update • Oct 16

Pharma Contracts And R&D Will Drive Growth Amid Price Pressures

Analysts have modestly increased their price target for Avantor, raising it by $0.28 to $14.40. They cite revised expectations for end market recovery and alignment with company outlooks.
Seeking Alpha • Apr 26

Avantor: A Healthier Diagnosis As Expectations Cool

Summary Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio. The risk-reward profile has improved due to lower expectations, but the outlook remains cautious amidst continued sales declines and pending leadership changes. Read the full article on Seeking Alpha
Seeking Alpha • Mar 07

Avantor: Mundane Business, Solid Cash Flow, Potential New Risks

Summary Avantor, Inc. has seen a significant decline in its stock price recently. The company did divest itself of one business this summer, paying down some debt with the proceeds. In addition, the company delivered an impressive amount of free cash flow in FY2024. Buy, Sell or Hold?  An analysis around AVTR stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Dec 18

Avantor: Durable FCF Generator Trading For Cheap

Summary Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor’s leadership in the biopharma industry and shifting revenue mix can produce considerable margin expansion. Significant FCF generation can improve the company’s capital structure and return value to shareholders. Potential industry inflection point creates optimal entry point with multiple expansion. Read the full article on Seeking Alpha

Shareholder Returns

AVTRUS Life SciencesUS Market
7D4.8%8.8%0.5%
1Y24.2%31.7%12.0%

Return vs Industry: AVTR underperformed the US Life Sciences industry which returned 31.7% over the past year.

Return vs Market: AVTR exceeded the US Market which returned 12% over the past year.

Price Volatility

Is AVTR's price volatile compared to industry and market?
AVTR volatility
AVTR Average Weekly Movement7.0%
Life Sciences Industry Average Movement7.2%
Market Average Movement6.8%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market2.9%

Stable Share Price: AVTR has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: AVTR's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
190413,500Emmanuel Lignerwww.avantorsciences.com

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies.

Avantor, Inc. Fundamentals Summary

How do Avantor's earnings and revenue compare to its market cap?
AVTR fundamental statistics
Market capUS$10.73b
Earnings (TTM)-US$578.00m
Revenue (TTM)US$6.56b
1.6x
P/S Ratio
-18.2x
P/E Ratio

Is AVTR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVTR income statement (TTM)
RevenueUS$6.56b
Cost of RevenueUS$4.47b
Gross ProfitUS$2.09b
Other ExpensesUS$2.67b
Earnings-US$578.00m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.85
Gross Margin31.83%
Net Profit Margin-8.81%
Debt/Equity Ratio65.2%

How did AVTR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/18 21:49
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Avantor, Inc. is covered by 30 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert BambergerBaird
Catherine Ramsey SchulteBaird
Luke SergottBarclays

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide